TITLE

NCI Study Demonstrates Significant Overall Survival and Time-to-Next-Treatment Benefits for BiovaxID(r) Cancer Vaccine Following Rituximab-Chemotherapy in Mantle Cell Lymphoma Study

PUB. DATE
June 2012
SOURCE
Biomedical Market Newsletter;6/7/2012, Vol. 21, p1
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports on an announcement made by Biovest International Inc., subsidiary of Accentia Biopharmaceuticals Inc. related to the release of the outcomes of the Phase II BiovaxID lymphoma vaccine clinical trial by the U.S. National Cancer Institute (NCI). It informs that the results were announced at the 2012 American Society of Clinical Oncology Annual Meeting (ASCO 2012). As per Wyndham H. Wilson, chief executive officer (CEO) of the company, the results are very pleasing.
ACCESSION #
77282968

 

Related Articles

  • Biovest Announces that New Clinical Data for BiovaxID(r) Personalized Cancer Vaccine will be Presented by National Cancer Institute at ASCO.  // Biomedical Market Newsletter;5/7/2012, Vol. 21, p1 

    The article presents information on an announcement made by the subsidiary company of biotechnology company Accentia Biopharmaceuticals Inc. named Biovest International Inc. based on the data of phase two of the clinical trial of mantle cell lymphoma. The trial was conducted at the National...

  • BiovaxID(r) Personalized Lymphoma Vaccine is Featured in Article Published in HemOnc Today.  // Biomedical Market Newsletter;2/7/2012, Vol. 21, p1 

    The article informs that Biovest International Inc., a subsidiary company of Accentia Biopharmaceuticals Inc. has announced the publication of an article related to BiovaxID(r), a personalized cancer vaccine for incurable lymphomas. The article also includes the interview of the clinical...

  • Panel's Nod on Lymphoma Trial Ramps Up Success Speculation. Hollingsworth, Catherine // BioWorld Today;4/18/2008, Vol. 19 Issue 76, p1 

    The article reports on an announcement by Tampa, Florida-based Biovest International Inc. that an independent committee reviewing its BiovaxID cancer vaccine trial has called for the unblinding of study data for conducting a final analysis. The shares of Accentia Biopharmaceuticals, parent...

  • Interim Data Hint at Survival Boost with Cancer Vaccine. Turner, Tiffany // BioWorld Today;6/12/2008, Vol. 19 Issue 114, p1 

    The article reports on the 24 percent increase of the share price of Accentia Biopharmaceuticals on June 11, 2008. The increase was caused by news that its majority-owned subsidiary Biovest International Inc. reported positive interim results from a blinded, pivotal Phase III trial of its...

  • Biovest Announces BiovaxID(r) ASCO Abstract Available On-line; NCI to Present Cancer Vaccine Data from Mantle Cell Lymphoma Study.  // Biomedical Market Newsletter;5/18/2012, Vol. 21, p1 

    The article informs that the result of the clinical trial of BiovaxID which has been conducted by the U.S. National Cancer Institute (NCI) is available on-line on its web site. It informs that the results will be presented by NCI at the 2012 American Society of Clinical Oncology Annual Meeting...

  • Biovest's Eligibility to Seek EU Marketing Approval for its BiovaxID Cancer Vaccine as Orphan Drug Confirmed by EMA.  // Biomedical Market Newsletter;7/19/2012, Vol. 21, p1 

    The article informs that Biovest International Inc. has received formal notification from the European Medicines Agency regarding the marketing of BiovaxID as an orphan medicinal product. It mentions that BiovaxID is used for the treatment of follicular nonHodgkin's lymphoma. It further informs...

  • Accentia acquires controlling interest in Biovest International.  // PharmaWatch: Biotechnology;August 2003, Vol. 2 Issue 8, p21 

    Reports on the acquisition of Biovest International Inc.'s controlling equity interest by Accentia Inc. Objectives under the acquisition; Plan of Biovest to expand its core businesses of contract biologic production; Benefits of the acquisition for parties concerned.

  • Conquering Cancer. Kay, William // Equities;Apr2007, Vol. 55 Issue 2, p20 

    The article presents information on several U.S. companies that are developing ways to treat cancer. It states that a vertically-integrated company that buys, develops and markets drugs has been created by Florida-based Accentia Biopharmaceuticals. Biovest International has developed its...

  • Accentia acquires controlling interest in Biovest International.  // PharmaWatch: Cancer;August 2003, Vol. 2 Issue 8, p22 

    Announces pharmaceutical company Accentia Inc.'s acquisition of a controlling equity interest in Biovest International. Purchase price; Other terms included in the deal.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics